The acquisition will help boost Ramarketing’s presence in North America and bring together the company’s work in strategy, marketing and communications with ISR’s work in research and insight. Both companies will retain their separate identities.

ISR is based at North Carolina’s Research Triangle Park and focuses on primary research-led syndicated and custom market research for the pharmaceutical outsourcing market, including contract development and manufacturing organisations (CDMOs), and contract and clinical research organisations (CROs).

Ramarketing works with pharmaceutical services and outsourcing organisations across Europe and North America, and is based in Newcastle upon Tyne.

Emma Banks, group chief executive at Ramarketing, said: “ISR adds depth to our commercial offer in a way that is practical and client-led. Its research capability strengthens how we help clients make informed growth decisions, while keeping insight, strategy and execution closely aligned.

“This is a capability-led investment rather than a structural overhaul. ISR retains its identity and research integrity, while gaining access to broader commercial support as part of the group.” 

Kate Hammeke, chief executive at ISR, said: “Being part of Ramarketing allows us to extend the impact of that work, giving clients stronger support in acting on insight without changing how we conduct or deliver our research.

“Our team, methodologies, and client relationships remain unchanged. What expands is the range of support available to clients as they translate research into commercial decisions.”